» Articles » PMID: 38166965

Impact of Comorbidities in COPD Clinical Control Criteria. The CLAVE Study

Overview
Journal BMC Pulm Med
Publisher Biomed Central
Specialty Pulmonary Medicine
Date 2024 Jan 3
PMID 38166965
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Chronic obstructive pulmonary disease (COPD) frequently coexists with other chronic diseases, namely comorbidities. They negatively impact prognosis, exacerbations and quality of life in COPD patients. However, no studies have been performed to explore the impact of these comorbidities on COPD clinical control criteria.

Research Question: Determine the relationship between individualized comorbidities and COPD clinical control criteria.

Study Design And Methods: Observational, multicenter, cross-sectional study performed in Spain involving 4801 patients with severe COPD (< 50 predicted forced expiratory volume in the first second [FEV%]). Clinical control criteria were defined by the combination of COPD assessment test (CAT) scores (≤16 vs ≥17) and exacerbations in the previous three months (none vs ≥1). Binary logistic regression adjusted by age and FEV% was performed to identify comorbidities potentially associated with the lack of control of COPD. Secondary endpoints were the relationship between individualized comorbidities with COPD assessment test and exacerbations within the last three months.

Results: Among 4801 patients with severe COPD (27.5% controlled and 72.5% uncontrolled), after adjustment by age and FEV%, comorbidities related to lack of clinical control were cardiovascular diseases (heart failure, peripheral vascular disease and atrial fibrillation; p < 0.0001), psychologic disorders (anxiety and depression; p < 0.0001), metabolic diseases (diabetes, arterial hypertension and abdominal obesity; p < 0.001), obstructive sleep apnea-hypopnea syndrome (p < 0.0001), anaemia (p = 0.015) and gastroesophageal reflux (p < 0.0001), which were related to previous exacerbations and COPD assessment test scores.

Interpretation: Comorbidities are related to health-related quality of life measured by the COPD assessment test scores and history of exacerbations in the previous three months.

Take-home Points: Study question: What is the impact of comorbidities on COPD clinical control criteria?

Citing Articles

Causal Associations Between Chronic Obstructive Pulmonary Disease and Common Comorbidities: Evidence from Comprehensive Genetic Methods.

Ji J, Zhao Q, Yuan J, Yuan Z, Gao N Int J Chron Obstruct Pulmon Dis. 2025; 20:601-610.

PMID: 40078930 PMC: 11899904. DOI: 10.2147/COPD.S498513.


A 7-point evidence-based care discharge protocol for patients hospitalized for exacerbation of COPD: consensus strategy and expert recommendation.

Salvi S, Ghorpade D, Nair S, Pinto L, Singh A, Venugopal K NPJ Prim Care Respir Med. 2024; 34(1):44.

PMID: 39706845 PMC: 11662074. DOI: 10.1038/s41533-024-00378-7.


Comorbidities reduce survival and quality of life in COPD with severe lung hyperinflation.

Ter Haar E, Slebos D, Klooster K, Pouwels S, Hartman J ERJ Open Res. 2024; 10(6).

PMID: 39559450 PMC: 11571074. DOI: 10.1183/23120541.00268-2024.


Investigating the causal links between obstructive sleep apnea and gastrointestinal diseases mediated by metabolic syndrome through mendelian randomization.

Zhang Z, Jiang C, Yin B, Wang H, Zong J, Yang T Sci Rep. 2024; 14(1):26247.

PMID: 39482370 PMC: 11528114. DOI: 10.1038/s41598-024-77471-x.


The Impact of Anemia on Long-Term Mortality in Hospitalized Patients with Exacerbation of Chronic Obstructive Pulmonary Disease.

Garcia-Pachon E, Padilla-Navas I Int J Chron Obstruct Pulmon Dis. 2024; 19:2229-2237.

PMID: 39403170 PMC: 11471888. DOI: 10.2147/COPD.S469627.


References
1.
Divo M, Cote C, de Torres J, Casanova C, Marin J, Pinto-Plata V . Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012; 186(2):155-61. DOI: 10.1164/rccm.201201-0034OC. View

2.
Fabbri L, Luppi F, Beghe B, Rabe K . Complex chronic comorbidities of COPD. Eur Respir J. 2008; 31(1):204-12. DOI: 10.1183/09031936.00114307. View

3.
Celli B, Wedzicha J . Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease. N Engl J Med. 2019; 381(13):1257-1266. DOI: 10.1056/NEJMra1900500. View

4.
Wacker M, Jorres R, Karch A, Wilke S, Heinrich J, Karrasch S . Assessing health-related quality of life in COPD: comparing generic and disease-specific instruments with focus on comorbidities. BMC Pulm Med. 2016; 16(1):70. PMC: 4862227. DOI: 10.1186/s12890-016-0238-9. View

5.
Mannino D, Thorn D, Swensen A, Holguin F . Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008; 32(4):962-9. DOI: 10.1183/09031936.00012408. View